VALBIOTIS SA
Valbiotis announces that it has received Food and Drug Administration approval for New Dietary Ingredient status 11-Dec-2023 / 20:02 CET/CEST
Dissemination of a French.
These authorizations enable the simultaneous launch of recruitment for these international studies, which should be completed in the first half of 2023. The INSIGHT and INSIGHT 2 randomized
The INSIGHT international, multicenter, randomized, placebo-controlled pivotal Phase II/III clinical study will be conducted with a 3.7 g/day dose of TOTUM•854 on 400 volunteers; The INSIGHT